Elm Street Ventures
27
8M
19
1.50
0.30
6
- Stages of investment
- Areas of investment
Summary
The main department of described VC is located in the New Haven. The venture was found in North America in United States.
The current fund was established by Rob Bettigole. The overall number of key employees were 3.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Elm Street Ventures, startups are often financed by Connecticut Innovations, OUP (Osage University Partners), MPM Capital. The meaningful sponsors for the fund in investment in the same round are Connecticut Innovations, OUP (Osage University Partners), Xeraya Capital. In the next rounds fund is usually obtained by RA Capital Management, OrbiMed, New Leaf Venture Partners.
Deals in the range of 5 - 10 millions dollars are the general things for fund. Comparing to the other companies, this Elm Street Ventures performs on 4 percentage points more the average number of lead investments. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2009. Considering the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The higher amount of exits for fund were in 2019.
Among the most popular portfolio startups of the fund, we may highlight Iconic Therapeutics, Retail Optimization, SeeClickFix. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Consumer.
Investments analytics
Analytics
- Total investments
- 27
- Lead investments
- 0
- Exits
- 6
- Rounds per year
- 1.50
- Follow on index
- 0.30
- Investments by industry
- Biotechnology (20)
- Biopharma (6)
- Renewable Energy (6)
- Chemical (6)
- Health Care (6) Show 30 more
- Investments by region
-
- United States (27)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 12M
- Group Appearance index
- 0.93
- Avg. company exit year
- 6
- Avg. multiplicator
- 1.48
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Artizan Biosciences | 01 Mar 2021 | Biotechnology, Life Science, Biopharma | Early Stage Venture | 18M | United States, New York, New York |
Cloudsmith | 21 Sep 2021 | Software, SaaS, Security, Cloud Computing, Developer Tools | Early Stage Venture | 15M | Northern Ireland, Belfast, United Kingdom |
Immersive Systems | 01 Jan 2020 | Mobile, Gaming, eSports, News, Digital Media, Social News | Seed | 1M | United States, Pennsylvania, Pittsburgh |
Infectious | 01 Jan 2007 | Manufacturing, iOS, Art | Seed | 750K | United States, California, San Francisco |
P2 Science | 23 Feb 2023 | Biotechnology, Renewable Energy, Chemical | Late Stage Venture | United States, Connecticut | |
Soundbite Medical Solutions | 05 May 2016 | Health Care, Manufacturing, Medical Device | Seed | 2M | Quebec, Montreal, Canada |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.